Today's Top SOA Links
From the Wires
Cytovance(R) Biologics to Expand Production Capabilities in 2013
By: Marketwired .
Jan. 29, 2013 04:00 AM
OKLAHOMA CITY, OK -- (Marketwire) -- 01/29/13 -- Cytovance® Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, announced today that it will expand its current mammalian production capabilities to include a 1,000L SUB bioreactor, a 5,000L stainless steel bioreactor and an automated fill/finish line.
Cytovance Biologics currently specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 1,000L (w/v) from batch, fed-batch and perfusion processes and microbial production up to the 100L scale. The 1,000L and 5,000L bioreactors will complement the existing manufacturing process trains that include 100L, 500L and 1,000L bioreactors, 100L wave system, 20L and 200L Sartorius subs and a 100L microbial manufacturing train. The new bioreactors will be operational by the end of 2013 or early 2014.
Cytovance currently offers semi-automated aseptic vial fill/finish. With the addition of the Chase-Logeman fill/finish system, the increased capabilities will support vial sizes from 2mL to 100mL, batch sizes ranging from a few hundred vials to 20,000 or more and includes 100% weight check. The automated fill/finish service line will meet all FDA and EU regulatory requirements and is scheduled to be fully operational in the third quarter of 2013.
"To meet market and customer demands, we have decided to expand our capabilities in 2013 with the larger bioreactor and fill/finish automation," commented Darren Head, Cytovance President & CEO. "The increase in capabilities will allow Cytovance to provide clinical material to key clients as they move though the clinic and into commercial."
Cytovance continues to provide analytical method development and process development for phase I, II, and III clinical trial materials as well as regulatory expertise to support validation and commercial market launch for therapeutic proteins, recombinant proteins and monoclonal antibodies.
About Cytovance® Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.
Cytovance Media Contact
Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week